efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 34 Diseases   9 Trials   9 Trials   673 News 


12345678»
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  Impact of switching from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition. (Pubmed Central) -  Jan 29, 2025   
    Our results suggest switching from EFV/F/TDF to B/F/TAF significantly improves psychiatric symptoms and sleep quality. Neurocognitive performance remained stable, although a decline in NPZ-12 and in specific domains was observed.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
    Journal, HEOR, Patient reported outcomes:  De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: Acceptance, patient-reported outcomes, and cost savings in a multicentre study. (Pubmed Central) -  Nov 14, 2024   
    Results are consistent, with no clinically meaningful differences between arms for all RBC folate outcomes, and they suggest that cellular uptake of folate and folate transport to the infant do not differ in pregnant women starting DTG- versus EFV-based antiretroviral therapy. De-simplification from an STR to a TTR within the Dutch healthcare setting has been demonstrated as feasible, leads to significant cost reductions and should be discussed with every eligible person with HIV in the Netherlands.
  • ||||||||||  Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
    Journal:  Rapid viral suppression using integrase inhibitors during acute HIV-1 infection. (Pubmed Central) -  Nov 6, 2024   
    INSTI-based ART during AHI resulted in rapid and sustained viral suppression. Over 96?weeks, weight increased in the INSTI-based cohort but was similar to weight increase in a historical NNRTI-based AHI cohort.
  • ||||||||||  Pifeltro (doravirine) / Merck (MSD)
    Viral blips in the doravirine phase III clinical trials DRIVE?FORWARD and DRIVE?AHEAD () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_172;    
    Since treatment is lifelong, and resistance impacts current and future treatment options, clinicians should include the differential risk of TE-RAMs in shared-decision making discussions when switching ART in stable, suppressed individuals. Summary of viral blips in DRIVE-FORWARD and DRIVE-AHEAD DRIVE-FORWARD (1439-018) DRIVE-AHEAD (1439A-021) Double-blind phase (day 1
  • ||||||||||  efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
    Biomarker, Clinical, Journal:  Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial. (Pubmed Central) -  Sep 9, 2024   
    Summary of viral blips in DRIVE-FORWARD and DRIVE-AHEAD DRIVE-FORWARD (1439-018) DRIVE-AHEAD (1439A-021) Double-blind phase (day 1 Markers of bone and renal toxicity did not differ significantly through week 50 postpartum among women randomized to start DTG + FTC/TAF or DTG + FTC/TDF or EFV/FTC/TDF in pregnancy.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Complexities of Managing Chronic Hepatitis B in HIV: A Case of Acute Liver Injury Post-Medication Change (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3544;    
    On further history-taking, she reported a recent change in her HIV medication regimen from Efavirenz/Emtricitabine/Tenofovir to Dolutegravir/Rilpivirine in view of her worsening kidney function...Treatment with Entecavir and Lamivudine was initiated...As in our case, pegylated interferon or nucleos(t)ide analogues can be given to curb liver disease progression in affected individuals. Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Dovato (dolutegravir/lamivudine) / ViiV Healthcare
    A comparative study evaluating renal outcomes after switching from TDF+FTC+EFV To TDF/3TC/DTG (TLD) versus DTG+3TC in virologically suppressed Thai PWH (Poster board: 079) -  May 2, 2024 - Abstract #AIDS2024AIDS_1286;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. (Pubmed Central) -  Mar 26, 2024   
    This randomized, open-label, noninferiority trial enrolled participants living with HIV with no antiretroviral exposure in the previous 6 months to 1 of the following arms: tenofovir alafenamide (TAF) / emtricitabine (FTC) + dolutegravir (DTG) (2 tablets), tenofovir disoproxil fumarate (TDF) / FTC + DTG (2 tablets), or a fixed-dose combination of TDF / FTC / efavirenz (EFV) (1 tablet)...Repeat consent from the original 351 participants randomized to each arm was obtained from 230 participants (66%) in the TAF/FTC + DTG arm, 209 (60%) in the TDF/FTC + DTG arm, and 183 (52%) in the TDF/FTC/EFV arm...High viral suppression was seen across arms, with no resistance to DTG. Weight gain continued but slowed after 96 weeks, with few clinical events or laboratory changes.
  • ||||||||||  Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
    Trial completion:  Effects of Switching From ATRIPLA (clinicaltrials.gov) -  Feb 22, 2024   
    P2,  N=86, Completed, 
    Generic substitution of antiretrovirals for HIV-Tx and PrEP was well tolerated, with ?2% incidence of mild-moderate PSI ADRs. Active, not recruiting --> Completed
  • ||||||||||  Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
    Phase classification:  Effects of Switching From ATRIPLA (clinicaltrials.gov) -  Jan 11, 2024   
    P2,  N=86, Active, not recruiting, 
    Active, not recruiting --> Completed Phase classification: P2b --> P2
  • ||||||||||  efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
    Observational data, Retrospective data, Journal:  Associated factors for prediabetes in patients with human immunodeficiency virus (Pubmed Central) -  Nov 11, 2023   
    The main associated factor was the consumption of Atripla. This study has clinical relevance since it will allow the implementation of prevention, diagnosis and treatment strategies for prediabetes in order to reduce associated morbidity and mortality.
  • ||||||||||  Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
    Trial completion:  DRIVE-AHEAD: Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA (clinicaltrials.gov) -  Oct 10, 2023   
    P3,  N=734, Completed, 
    This study has clinical relevance since it will allow the implementation of prevention, diagnosis and treatment strategies for prediabetes in order to reduce associated morbidity and mortality. Active, not recruiting --> Completed
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Off-label use of long-acting injectable cabotegravir/rilpivirine in viremic patient living with HIV (ePosters) -  Oct 8, 2023 - Abstract #EACS2023EACS_1518;    
    Our case demonstrates the usefulness of CAB/RPV-LA in a patient not VS. The results add validity to the existing data on its use (1) and are optimistic so far with HIV-RNA <50 copies/mL However, our results are short-term, and follow-up studies are needed to clarify long-term outcomes.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Off-label use of long-acting injectable cabotegravir/rilpivirine in viremic patient living with HIV (ePosters) -  Oct 8, 2023 - Abstract #EACS2023EACS_1517;    
    Our case demonstrates the usefulness of CAB/RPV-LA in a patient not VS. The results add validity to the existing data on its use (1) and are optimistic so far with HIV-RNA <50 copies/mL However, our results are short-term, and follow-up studies are needed to clarify long-term outcomes.
  • ||||||||||  Journal:  Risks of metabolic syndrome in the ADVANCE and NAMSAL trials. (Pubmed Central) -  Oct 4, 2023   
    In this analysis, we highlight treatment-emergent metabolic syndrome associated with dolutegravir, likely driven by obesity. Clinicians initiating or monitoring patients on INSTI-based ART must counsel for lifestyle optimisation to prevent these effects.
  • ||||||||||  efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
    Effects of Atripla () -  May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1043;    
    Ibalizumab was also safe, well tolerated, and had been proven effective against multiple drug-resistant strains of viruses. Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
  • ||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
    Trial completion, Head-to-Head:  ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (clinicaltrials.gov) -  Nov 2, 2022   
    P3,  N=1110, Completed, 
    Participants switching either TAF/FTC+DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low density lipoprotein, triglycerides, glucose and glycated haemoglobin. Active, not recruiting --> Completed
  • ||||||||||  efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
    Journal:  Systematic post-mortem analysis of brain tissue from an HIV-1 subtype C viremic decedent revealed a paucity of infection and pathology. (Pubmed Central) -  Oct 7, 2022   
    This study reports a 38-year-old Zambian female decedent with severe wasting who was on Atripla for antiretroviral therapy...Overall, HIV detection was random, with low viral copies detected by quantitative polymerase chain reaction (qPCR); the lowest was observed in the occipital (median, IQR, range) 0.0 [0.0-0.0], 0.0-31.3, and the highest in the basal ganglia (mean ± SD, range, 125.1149.5, 0.0-350.0). Significant differences in HIV-1 DNA distribution were observed between the occipital versus parietal (p = 0.049), occipital versus frontal (p = 0.019), occipital versus basal ganglia (p = 0.005), cerebellum versus frontal (p = 0.021), cerebellum versus basal ganglia (p = 0.007), and temporal versus frontal (p = 0.034).
  • ||||||||||  Pifeltro (doravirine) / Merck (MSD)
    Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_278;    
    Switching to DOR resulted in weight loss or stable weight in most participants in three phase III trials, though weight change may differ by race, sex, and prior regimen. Because the proportions of women and black participants in the trials were low, further research is needed to better characterize the patient profile and mechanism for weight loss/stable weight with doravirine.
  • ||||||||||  Symfi (efavirenz/lamivudine/tenofovir disoproxil fumarate) / Mylan, dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods, dolutegravir/emtricitabine/tenofovir alafenamide (DTG/FTC/TAF) / Mylan
    Long-term risks of clinical obesity in the ADVANCE, NAMSAL and VISEND trials () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_274;    
    Across three randomised trials in 2867 patients, the risks of clinical obesity were significantly higher for DTG-based treatment, especially when combined with TAF/FTC. The adverse consequences of clinical obesity (e.g. diabetes, myocardial infarction) need to be factored into decisions on starting or switching to TAF/FTC/DTG, especially if already overweight at baseline.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Trial termination:  B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults (clinicaltrials.gov) -  Aug 17, 2022   
    P4,  N=30, Terminated, 
    Overall, this study showed that immune suppression and polypharmacy as a consequence of opportunistic infection prophylaxis are important factors contributing to the increased risk of ADRs among PLWH. Completed --> Terminated; Difficulties enrolling participants